Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
USE CASES
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
PatSnap Eureka Desktop
NEWAnalytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
NEWServices professionnels
Cabinets d'avocats
Sciences de la vie
Haute technologie
Competitor Tech Research
Design Risk Screening
Telecom SEP Claim Chart
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport How do FXR agonists, THRβ agonists, and ACC inhibitors differ in targeting MASH? Mechanistic analysis and pipeline combination strategy evidence.
Article | Rapport Meta-analysis comparing lecanemab and donanemab vs placebo across ADCOMS, CDR-SB, ADAS-Cog 14, and amyloid PET in early Alzheimer's disease. Full effect sizes, CIs, and heterogeneity data.
Article | Rapport DESTINY-Breast04's updated 32-month follow-up confirms T-DXd's OS and PFS benefit in HER2-low mBC, with key findings on ILD safety, ER-low subgroups, and ADC positioning.
Article | Rapport Analyse THRβ agonist selectivity SAR, hepatic uptake optimisation, ADME/PK profiles, and structural strategies that reduce cardiac and bone off-target effects vs non-selective THR agonists.
Article | Rapport Analyse asundexian's oxopyridine scaffold, sub-nanomolar FXIa potency (Ki 0.26 nM), >38,000-fold selectivity over Factor Xa and thrombin, and structural differentiation from DOAC chemical series.
Article | Rapport Voclosporin vs cyclosporine A: structural modifications, SAR patterns, nephrotoxicity reduction data, ADME/PK profile, and pharmacophore features in IgA nephropathy.
Article | Rapport Deep-dive into Tarlatamab (AMG 757) BiTE architecture: DLL3-binding SAR, CD3 affinity tuning, bivalency data, and how it outperforms earlier DLL3 bispecifics.
Article | Rapport Deep patent analysis of tezepelumab: CDR sequences, epitope binding data, Fc engineering for half-life extension, and structural differentiation from earlier anti-TSLP biologics.
Article | Rapport Long-term DESTINY-Breast04 data show T-DXd cuts death risk by 31–42% vs TPC across HR+, HR−, and ER-subgroups in HER2-low metastatic breast cancer.
Article | Rapport How to engineer polymer composites with high thermal conductivity and electrical insulation for power electronics: filler selection, hybrid architectures, and breakdown voltage strategies.
Article | Rapport PEM, alkaline, and solid oxide electrolyzer critical materials in 2026: iridium scarcity, patent trends, and the innovation pipeline shaping green hydrogen at scale.
Article | Rapport How to select and optimize polymer resin systems for low-dielectric 5G copper clad laminates. Dk/Df targets, filler design, and thermal stability strategies.
Article | Rapport Iptacopan and danicopan vs eculizumab and ravulizumab in PNH: mechanistic rationale for proximal vs terminal complement inhibition and EVH control evidence.
Article | Rapport How do sulfide, oxide, and polymer solid-state electrolytes compare in 2026? Ionic conductivity, stability, and patent trends analysed from 539 filings.
Article | Rapport Silicone, DLC, sol-gel ceramics, bio-based polymers, and plasma films mapped against PFAS performance benchmarks and 2025–2027 regulatory deadlines.